Premera Blue Cross does cover Zepbound for weight management, but only when your employer has specifically added weight-loss drug coverage to the plan and you meet Premera’s prior authorization criteria. If the benefit was not elected, Zepbound is excluded no matter how strong the medical case. If it was elected, approval still runs through clinical rules on BMI, lifestyle efforts, and comorbidities.
Check Whether Your Plan Includes the Benefit
This is the first thing to confirm, because everything else depends on it. Premera classifies weight-loss GLP-1 medications like Zepbound as an “employer-elected benefit,” meaning each employer group chooses whether to include them.1Premera Blue Cross. February Premera Formulary Newsletter Premera’s own pharmacy policy says it directly: “Drugs for weight management are excluded under many benefit plans.”2Premera Blue Cross. Pharmacy Policy 5.01.621 – Drugs for Weight Management
The quickest way to find out where you stand is to read your benefit plan document or call the member services number on the back of your card and ask specifically whether weight-loss drugs are covered. One important distinction: when tirzepatide is prescribed for type 2 diabetes (sold as Mounjaro), it is covered across all Premera plans under the standard diabetes policy.3Premera Blue Cross. GLP-1s Still Making Headlines Zepbound, which is the same molecule marketed for weight loss, sits in the elective bucket.
Clinical Criteria for Chronic Weight Management
If your plan does include the benefit, Premera still requires prior authorization. Under the pharmacy policy effective April 1, 2026, you have to meet all of the following for weight management approval:2Premera Blue Cross. Pharmacy Policy 5.01.621 – Drugs for Weight Management
- You are 18 or older.
- You have documented at least three months of behavioral modification and dietary restriction before starting the drug.
- Your BMI is 30 or higher, or 27 or higher with at least one weight-related comorbidity. Qualifying conditions include hypertension, type 2 diabetes, dyslipidemia, cardiovascular disease, coronary artery disease, obstructive sleep apnea, asthma, COPD, knee osteoarthritis, metabolic-dysfunction associated steatotic liver disease (formerly NAFLD), and polycystic ovarian syndrome.
- You will use Zepbound alongside a reduced-calorie diet and increased physical activity.
- You are not taking another weight-loss drug concurrently, including phentermine, Contrave, Saxenda, Wegovy, Qsymia, Xenical, or Alli.
One thing Premera does not require for Zepbound is step therapy. You do not have to try and fail another weight-loss medication first, which is a condition the policy does impose on some older drugs like Qsymia and Saxenda.2Premera Blue Cross. Pharmacy Policy 5.01.621 – Drugs for Weight Management
The Sleep Apnea Pathway
Zepbound can also be approved for adults with moderate to severe obstructive sleep apnea and obesity. The requirements are a BMI of 30 or higher, a sleep study within the past 12 months showing an apnea-hypopnea index of at least 15 events per hour, and no diagnosis of central sleep apnea (where central events account for more than 50 percent of apneas or hypopneas) or Cheyne-Stokes respiration.2Premera Blue Cross. Pharmacy Policy 5.01.621 – Drugs for Weight Management
This indication matters because it is a separate route to coverage. If your plan has limitations tied specifically to weight management, a qualifying OSA diagnosis may open a different door. It is worth raising with your prescriber if you have symptoms of sleep apnea that have not been evaluated.
Dose Limits and How Long Approvals Last
Premera caps Zepbound at 15 mg once weekly. Per 28-day fill, you can get four prefilled pens or single-dose vials, or one KwikPen or multi-dose vial. These limits apply to both the weight management and OSA indications.2Premera Blue Cross. Pharmacy Policy 5.01.621 – Drugs for Weight Management
An initial authorization for weight management runs up to seven months. For OSA, the initial window is 12 months. After that, you can be re-authorized for a year at a time if you show clinical benefit. For weight management, that means at least a 5 percent reduction from baseline body weight at the seven-month mark plus continued adherence to diet and exercise. For OSA, the renewal threshold is at least 10 percent weight loss after 12 months.4OpenPayer. Premera BlueCross Weight Management Coverage Criteria
If Your Request Is Denied
Read the denial letter first. It will tell you the specific reason and which clinical criteria Premera applied.5Premera Blue Cross. Understanding the Level 1 Appeals Process Denials usually come down to one of three things: the plan excludes weight-loss drugs entirely, prior authorization requirements were not met, or the clinical documentation was incomplete.
If the plan covers the benefit and the denial was clinical, work with your prescriber on a Level 1 appeal. Premera’s appeals team, which includes nurses and physicians, reviews the file along with any new documentation you submit.5Premera Blue Cross. Understanding the Level 1 Appeals Process If that is denied, the letter will explain the next step, typically an external independent review. External reviews overturn roughly 40 percent of denials, yet fewer than 1 percent of denied claims are ever appealed.
A stronger appeal usually comes down to a thorough letter of medical necessity from the prescriber covering BMI, weight history, comorbidities, and prior treatments attempted, filed before the deadline printed on the denial letter.5Premera Blue Cross. Understanding the Level 1 Appeals Process If the plan categorically excludes weight-loss drugs, medical necessity arguments will not change the outcome because the exclusion is a benefit-design decision rather than a clinical one. In that case, talk with your provider about whether the OSA pathway could apply.
Washington Court Ruling on Weight-Loss Exclusions
Premera is based in Washington, and a 2026 ruling there could eventually affect how insurers handle these exclusions. On May 4, 2026, the Washington Court of Appeals held in Simonton v. Washington State Health Care Authority that blanket insurance exclusions for weight-loss medications may violate the Washington Law Against Discrimination.6Washington Courts. Simonton v. Washington State Health Care Authority, No. 86988-4-I Because Washington recognizes obesity as a disability, the court said an insurer cannot refuse to cover treatment for that disability “for no reason other than because it had always done so.”7The Spokesman-Review. GLP-1s Weight Loss Drugs May Soon Be Covered by Health Insurance
The decision does not force plans to start covering Zepbound today. It sent the case back to a lower court to decide whether the Health Care Authority had a reasonable justification for denying coverage in that plaintiff’s situation, and insurers can still exclude drugs they show are experimental, ineffective, or not cost-effective. Attorneys involved estimate the trial court phase could take up to a year, with possible further appeals to the Washington Supreme Court.8The Seattle Times. Insurance Won’t Cover Ozempic — WA Court Sparks Discrimination Debate
A legislative fix has not materialized either. Washington HB 1326, which would have required insurers to cover FDA-approved obesity medications starting January 1, 2026, died in committee in March 2026.9BillTrack50. WA HB1326 – Concerning the Diabetes Prevention and Obesity Treatment Act A companion bill, SB 5353, was reintroduced and retained in the 2025–2026 session but has not advanced.10LegiScan. WA SB5353 Supplement For now, there is no state mandate in Washington requiring weight-loss drug coverage, and your plan’s elected benefits remain the controlling factor.